J. Goldman & Co’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.36M Sell
14,988
-1,198
-7% -$396K 0.09% 255
2026
Q2
$5.42M Buy
16,186
+522
+3% +$165K 0.14% 191
2026
Q1
$5.05M Buy
15,664
+10,114
+182% +$3.13M 0.15% 187
2025
Q4
$1.64M Buy
+5,550
New +$1.03M 0.04% 341
2025
Q1
– Sell
-11,634
Closed -$895K – 596
2024
Q4
$895K Buy
+11,634
New +$842K 0.02% 334
2024
Q2
– Sell
-12,336
Closed -$753K – 558
2024
Q1
$753K Sell
12,336
-5,664
-31% -$254K 0.02% 293
2023
Q4
$401K Hold
18,000
– – 0.02% 273
2023
Q3
$462K Hold
18,000
– – 0.02% 280
2023
Q2
$310K Buy
18,000
+9,000
+100% +$138K 0.01% 309
2023
Q1
$109K Buy
+9,000
New +$380K ﹤0.01% 330

Other funds holding PRAX

J. Goldman & Co's PRAX Position: Q3 2026 in Review

J. Goldman & Co reduced its Praxis Precision Medicines (PRAX) stake by 7.4% in Q3 2026, selling an estimated $396K and leaving 14,988 shares worth $4.36M. The position accounts for 0.09% of the portfolio, ranked #255.

J. Goldman & Co first reported a position in PRAX in Q1 2023 and has held it in 10 quarters since. The position peaked at $5.42M in Q2 2026. 339 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • J. Goldman & Co held 14,988 shares of Praxis Precision Medicines worth $4.36M as of Q3 2026.
  • J. Goldman & Co sold 1,198 Praxis Precision Medicines shares in Q3 2026, an estimated $396K.
  • Praxis Precision Medicines made up 0.09% of J. Goldman & Co's portfolio in Q3 2026, its #255 holding.
  • J. Goldman & Co first reported a position in Praxis Precision Medicines in Q1 2023 and has held it in 10 quarters since.
  • J. Goldman & Co's Praxis Precision Medicines position peaked at $5.42M in Q2 2026.
  • 339 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on J. Goldman & Co's 13F filing for Q3 2026, filed 16 Nov 2026.